Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical procedures performed using the company’s groundbreaking imaging technology.
The registry will support future product development and continuously enhance the AI deep-learning model behind Perimeter’s investigational next-generation technology. By leveraging real-world clinical data and images, Perimeter aims to further make its AI model even more sophisticated. The registry also enables surgeons to contribute retrospective data and track patient outcomes, helping to evaluate surgical results over time.
In a statement, Dr. Jennifer Tittensor, a general surgeon for Timpanogos Regional Hospital and the first contributor to the OCT-Tissue Registry, said, “I have used Perimeter’s OCT technology in more than 120 surgeries, and it has become an invaluable tool. In my practice, it helps me assess margins in real-time and decide whether I need to remove more tissue – potentially avoiding the need for a second surgery. Being a part of the registry allows me to track and analyze patient outcomes and help shape future improvements in the technology. I am excited to be involved.”
Adrian Mendes, CEO of Perimeter, remarked, “The launch of this registry provides an opportunity to patients and surgeons to help future patients have better clinical care. We look forward to collaborating with physicians to collect high-quality data and images from a broad and diverse patient population. The more images we can gather from the widest range of patients, the better we can train our AI algorithm to detect patterns in various tissue types. This registry could potentially help physicians provide more personalized care, achieve clean margins more frequently, and reduce the need for second surgeries due to residual cancer.”
Perimeter’s S-Series OCT utilizes the company’s patented wide-field optical coherence tomography technology to enable surgeons to visualize tissue specimens in real-time, with ultra-high resolution, during surgery. Building on this foundation, the investigational next-generation B-Series OCT with ImgAssist AI 2.0, under premarket approval review by the FDA, integrates AI and is intended to help surgeons more efficiently detect suspicious tissue during breast conserving surgery.
